The S100A8/A9 Heterodimer Amplifies Proinflammatory Cytokine Production by Macrophages Via Activation of Nuclear Factor Kappa B and P38 Mitogen-activated Protein Kinase in Rheumatoid Arthritis
Overview
Authors
Affiliations
S100A8 and S100A9, two Ca2+-binding proteins of the S100 family, are secreted as a heterodimeric complex (S100A8/A9) from neutrophils and monocytes/macrophages. Serum and synovial fluid levels of S100A8, S100A9, and S100A8/A9 were all higher in patients with rheumatoid arthritis (RA) than in patients with osteoarthritis (OA), with the S100A8/A9 heterodimer being prevalent. By two-color immunofluorescence labeling, S100A8/A9 antigens were found to be expressed mainly by infiltrating CD68+ macrophages in RA synovial tissue (ST). Isolated ST cells from patients with RA spontaneously released larger amounts of S100A8/A9 protein than did the cells from patients with OA. S100A8/A9 complexes, as well as S100A9 homodimers, stimulated the production of proinflammatory cytokines, such as tumor necrosis factor alpha, by purified monocytes and in vitro-differentiated macrophages. S100A8/A9-mediated cytokine production was suppressed significantly by p38 mitogen-activated protein kinase (MAPK) inhibitors and almost completely by nuclear factor kappa B (NF-kappaB) inhibitors. NF-kappaB activation was induced in S100A8/A9-stimulated monocytes, but this activity was not inhibited by p38 MAPK inhibitors. These results indicate that the S100A8/A9 heterodimer, secreted extracellularly from activated tissue macrophages, may amplify proinflammatory cytokine responses through activation of NF-kappaB and p38 MAPK pathways in RA.
Cai L, Lv Q, Ma R, Liu W, Guan Y, Huang Z Heliyon. 2025; 11(2):e41706.
PMID: 39877611 PMC: 11773035. DOI: 10.1016/j.heliyon.2025.e41706.
Cross K, Vetter S, Alam Y, Hasan M, Nath A, Leclerc E Biomolecules. 2025; 14(12.
PMID: 39766257 PMC: 11673996. DOI: 10.3390/biom14121550.
Trained innate immunity as a potential link between preeclampsia and future cardiovascular disease.
Carrasco-Wong I, Sanchez J, Gutierrez J, Chiarello D Front Endocrinol (Lausanne). 2025; 15:1500772.
PMID: 39741876 PMC: 11685753. DOI: 10.3389/fendo.2024.1500772.
Zhang Q, Yang D, Han X, Ren Y, Fan Y, Zhang C Eur J Med Res. 2024; 29(1):640.
PMID: 39741354 PMC: 11689566. DOI: 10.1186/s40001-024-02236-1.
Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity.
Demir M, Lin Y, Costa Cruz P, Tajima M, Honjo T, Muller E Front Immunol. 2024; 15:1479502.
PMID: 39497822 PMC: 11532050. DOI: 10.3389/fimmu.2024.1479502.